FDA LABEL RECORD
Tresiba
INSULIN DEGLUDEC. FDA prescribing information for this product, as published on the retrieval date below.
AS THE LABEL RECORDS IT
Product details
| Brand name | Tresiba |
|---|---|
| Generic name | INSULIN DEGLUDEC |
| Labeller | Novo Nordisk |
| Route | SUBCUTANEOUS |
| Label version | 14 |
| Effective | 2022-07-01 |
| Retrieved by this site | 2026-10-03 |
| Full label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=456c5e87-3dfd-46fa-8ac0-c6128d4c97c6 |
INDICATIONS AND USAGE
Quoted from the FDA label
1 INDICATIONS AND USAGE TRESIBA is indicated to improve glycemic control in patients 1 year of age and older with diabetes mellitus. Limitations of Use • Not recommended for the treatment of diabetic ketoacidosis. TRESIBA is a long-acting human insulin analog indicated to improve glycemic control in patients 1 year of age and older with diabetes mellitus ( 1 ). Limitations of Use: • Not recommended for the treatment of diabetic ketoacidosis.
What this page is
A reproduction of a public FDA label record. Everything quoted above is the labeller's wording as published by the FDA, not this site's. Nothing here is regulatory, legal or medical advice, and a label being reproduced says nothing about whether a product is available in any particular country. Labels are revised often; the retrieval date above says when this copy was taken, and the full current label is at the link.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.